To-BBB technologies BV Receives IND Approval for Novel Brain Cancer Drug, 2B3-101

Published: Aug 19, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEIDEN, the Netherlands--(BUSINESS WIRE)--to-BBB, the brain drug delivery company, is pleased to announce the successful completion of its 2B3-101 Phase I clinical trial in brain cancer patients, safely reaching clinically effective dosages. to-BBB is now ready to proceed to the Phase IIa part of this trial, treating patients with brain metastases from breast cancer, small cell lung cancer and melanomas, as well as patients with primary, malignant brain cancers (recurrent gliomas). With no commercially available treatments for brain metastases of solid tumors and no effective treatment alternatives in recurrent gliomas, 2B3-101 is targeting a high unmet medical need.

Help employers find you! Check out all the jobs and post your resume.

Back to news